Puma Biotechnology Inc. buy KongVestor
Start price
29.06.26
/
50%
€7.18
Target price
29.06.27
-
Performance (%)
-1.12%
End price
30.06.26
€7.10
Summary
This prediction ended on 30.06.26 with a price of €7.10. With a performance of -1.12%, the BUY prediction for Puma Biotechnology Inc. by KongVestor closed slightly in the red. KongVestor has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Puma Biotechnology Inc. | 3.510% | 3.510% |
| iShares Core DAX® | -1.586% | 5.028% |
| iShares Nasdaq 100 | -4.148% | -0.125% |
| iShares Nikkei 225® | -6.302% | 0.528% |
| iShares S&P 500 | -3.225% | 0.470% |